Search

everythinglearnresearchcommunity

for

Search:↓

The user shared a 3-month update on using a 5% minoxidil and finasteride topical solution enriched with redensyl and procapil for hair regrowth. They mentioned inconsistency in using the treatment and initially starting it without consulting a dermatologist.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.

A male in his early 40s, who experienced side effects from finasteride, used 2.5% topical spironolactone for one year with no side effects but minimal regrowth. He plans to try a 5% spironolactone solution next.

The user shared 5 months of progress using oral minoxidil and finasteride, along with rosemary and keto shampoos. They noted significant hair growth, including increased body hair, and attributed most progress to the medications.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

A user shared a 5-month progress picture showing hair regrowth from taking 1mg of finasteride daily. Another user reported significant hair regrowth and no side effects after 12 years on finasteride.

Low-Level Laser Therapy (LLLT) is considered expensive and may not provide significant benefits, with some users suggesting alternatives like finasteride, minoxidil, and microneedling. Many users report limited success with LLLT and similar treatments, recommending more proven options instead.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.

The conversation discusses hair loss treatments, specifically progesterone therapy with hydrocortisone butyrate, and the use of dutasteride and finasteride. Opinions vary on the effectiveness and side effects of these treatments, with some users advocating for acceptance of balding if treatments are not suitable.

Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The user has been using finasteride for five years and minoxidil foam for 1.5 years to combat hair loss, experiencing significant regrowth after an initial shedding phase with minoxidil. They shared progress pictures and discussed treatment experiences, including the addition of minoxidil to their regimen after noticing reduced efficacy with finasteride alone.

The user experienced significant hair improvement using 1mg finasteride and 2.5mg oral minoxidil daily, with most gains attributed to finasteride. They also stopped using topical treatments due to scalp psoriasis and reported no major side effects.

The conversation discusses whether age affects the side effects and effectiveness of hair loss treatments like finasteride and dutasteride. Some believe early treatment yields better results, while others mention varied outcomes across ages and personal regrowth experiences without a clear consensus on age impact.

The user has been using finasteride, minoxidil, retinoid, and occasional microneedling for hair loss with good results. They recently added stemoxydine, which improved their hair further, and suggest trying it, especially in the EU where it's easily available.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses using a 5% Topical Minoxidil with 0.01% Tretinoin serum for hair loss, noting its lack of propylene glycol to avoid itchiness and greasiness. Users share experiences with different Minoxidil formulations and discuss the effectiveness and stability of Tretinoin in various forms.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

A user who has been using Pyrilutamide for 5 months with no results, and other users suggesting they switch to RU58841 or stick to their treatment plan for at least one year.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.